CRESCENT BIOPHARMA, INC.
CBIONasdaq
$14.75
↓ -2.4%Jul 17 close · end-of-day
Price
1Y↑ +12.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$406.7M
Enterprise Value
$217.5M
P/E
—
P/S
37.5
P/B
2.2
EV/EBITDA
—
PEG
—
FCF Yield
-17.4%
Dividend Yield
—
Revenue (TTM)
$10.8M
Net Income (TTM)
-$93.0M
Free Cash Flow (TTM)
-$70.7M
Gross Margin
—
Operating Margin
-1504.4%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$189.2M
Return 1Y
+13.3%
Company profile
GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.
- CEO
- Harout Semerjian
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- Maryland
- Website
- glycomimetics.com
Management & directors
- Bispham Barbara HarlinSee Remarks
- Brumm Joshua TChief Executive Officer
- Im Ellie EunkyungChief Medical Officer
- Lynch RyanSee Remarks
- Mcneill JonathanPresident and COO
- Pinkas JanChief Scientific Officer
- Scalzo Richard WilliamChief Financial Officer
- Doughty Christopher GrantChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
CBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.0M—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.2M | $1.2M | $75,000.00 | $10,000.00 | — | $10.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$51.5M | -$63.4M | -$47.4M | -$39.3M | -$40.0M | -$152.6M |
| Net income | -$51.0M | -$63.4M | -$46.7M | -$36.9M | -$37.9M | -$153.9M |
| Diluted EPS | -$1.12 | -$1.23 | -$0.89 | -$0.58 | -$0.59 | — |
| Operating cash flow | -$39.2M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$71.5M |
| Free cash flow | -$39.3M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$72.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -506.8% | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Net margin | -502.1% | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | — | — | — | $1.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.4M | -$11.2M | -$17.2M | -$14.2M | -$21.0M | -$25.9M | -$91.5M | -$24.7M |
| Net income | -$10.1M | -$9.8M | -$17.9M | -$15.1M | -$21.8M | -$24.6M | -$23.3M | -$23.3M |
| Diluted EPS | -$0.16 | -$0.15 | -$0.24 | — | — | — | — | — |
| Operating cash flow | -$8.9M | -$8.0M | -$6.3M | -$10.9M | -$16.4M | -$17.5M | -$26.7M | -$8.9M |
| Free cash flow | -$8.9M | -$8.0M | -$6.3M | -$10.9M | -$16.5M | -$18.1M | -$26.9M | -$9.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -2380.1% |
| Net margin | — | — | — | — | — | — | — | -2240.9% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Brumm Joshua T· Chief Executive Officer | Sale | 42,305 | $17.99 | $761,066.95 | filing |
| 2026-06-22 | McNeill Jonathan· President and COO | Sale | 20,549 | $17.99 | $369,676.51 | filing |
| 2026-06-22 | Pinkas Jan· Chief Scientific Officer | Sale | 1,288 | $17.99 | $23,171.12 | filing |
| 2026-06-22 | Im Ellie Eunkyung· Chief Medical Officer | Sale | 1,219 | $17.99 | $21,929.81 | filing |
| 2026-06-22 | Bispham Barbara Harlin· See Remarks | Sale | 1,218 | $17.99 | $21,911.82 | filing |
| 2026-06-22 | Scalzo Richard William· Chief Financial Officer | Sale | 1,112 | $17.99 | $20,004.88 | filing |
| 2026-06-22 | Lynch Ryan· See Remarks | Sale | 465 | $17.99 | $8,365.35 | filing |
| 2025-12-15 | Scalzo Richard William· Chief Financial Officer | Award | 5,000 | — | — | filing |
| 2025-12-15 | McNeill Jonathan· President and COO | Award | 19,507 | — | — | filing |
| 2025-12-15 | McNeill Jonathan· President and COO | Award | 6,000 | — | — | filing |
| 2025-12-15 | Im Ellie Eunkyung· Chief Medical Officer | Award | 16,298 | — | — | filing |
| 2025-12-15 | Im Ellie Eunkyung· Chief Medical Officer | Award | 5,000 | — | — | filing |
| 2025-12-15 | Lynch Ryan· See Remarks | Award | 8,378 | — | — | filing |
| 2025-12-15 | Lynch Ryan· See Remarks | Award | 4,000 | — | — | filing |
| 2025-12-15 | Bispham Barbara Harlin· See Remarks | Award | 12,422 | — | — | filing |
| 2025-12-15 | Bispham Barbara Harlin· See Remarks | Award | 6,000 | — | — | filing |
| 2025-12-15 | Brumm Joshua T· Chief Executive Officer | Award | 10,000 | — | — | filing |
| 2025-12-15 | Pinkas Jan· Chief Scientific Officer | Award | 17,507 | — | — | filing |
| 2025-12-15 | Pinkas Jan· Chief Scientific Officer | Award | 5,000 | — | — | filing |
| 2025-12-15 | Doughty Christopher Grant· Chief Business Officer | Award | 14,714 | — | — | filing |
| 2025-12-15 | Doughty Christopher Grant· Chief Business Officer | Award | 8,000 | — | — | filing |
| 2025-12-15 | Brumm Joshua T· Chief Executive Officer | Award | 45,117 | — | — | filing |
| 2025-12-15 | Scalzo Richard William· Chief Financial Officer | Award | 14,422 | — | — | filing |
| 2025-12-04 | Fairmount Funds Management LLC | Buy | 1,360,000 | $13.41 | $18.2M | filing |
Latest 24 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.